B+
Bull case
25%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-09-24 · RankAlpha Sentiment Codex
SRZN
SurrozenFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The early IND submission supports execution, while DUET offers a defined path to initial clinical evidence. The June-quarter release reported $102.0 million in cash and a $5.0 million collaboration milestone.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Early-stage safety or efficacy results may fail to support differentiation from established retinal therapies.
Momentum
99
Value
41
Sentiment
21
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $18.00 · Bull $27.00 · Bear $8.00Analysis 2026-09-24; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-24 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $48.40
Why
Momentum99 · Δ7d -0.9
Value41 · Δ7d -0.1
Sentiment21 · Δ7d -5.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Early-stage safety or efficacy results may fail to support differentiation from established retinal therapies.
- • Regulatory or operational delays could postpone DUET initiation beyond management's year-end 2026 expectation.
- • DUET has not yet begun, clinical efficacy is unproven, and development spending may rise.
Catalyst clock
2026-12-31
DUET study initiation
Lead driver: Value · See fundamentals
Momentum
99
8% active weight
Current posture
7d trendFlat
Δ7d
-0.9
Δ21d
+13.6
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
21
45% active weight
Current posture
7d trendSoftening
Δ7d
-5.8
Δ21d
+8.1
Why this grade
Composite grade F. Momentum 99.0 / Value 40.6 / Sentiment 20.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-24. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-09-24 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-09-24 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$299.48M
Beta
0.58
Shares Out
11.75M
P/E (TTM) · Derived
-0.8
P/S (TTM)
45.43
P/FCF (TTM) · Derived
-8.02
Rev YoY
+408.6%
EPS YoY
-115.9%
Gross Margin
+98.1%
Op Margin
-385.3%
Net Debt
-$82.61M
Current Ratio
12.14
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data